Baecklund Eva, Natkunam Yasodha, Backlin Carin, Iliadou Anastasia, Askling Johan, Ekbom Anders, Feltelius Nils, Klareskog Lars, Enblad Gunilla, Lossos Izidore S, Levy Ronald, Sundström Christer, Rosenquist Richard
Department of Rheumatology, University Hospital, Uppsala, Sweden.
Br J Haematol. 2008 Apr;141(1):69-72. doi: 10.1111/j.1365-2141.2008.07011.x.
Diffuse large B-cell lymphomas (DLBCL) can be subdivided into germinal centre (GC)-like and non-GC-like subtypes by CD10, BCL6 and MUM1/IRF4 status. We previously reported that patients with severe rheumatoid arthritis (RA) are at increased risk of non-GC DLBCL. This study examined a new GC-marker, human germinal-centre-associated lymphoma (HGAL) protein, in RA-DLBCL. Of 111, 38 (34%) DLBCL were HGAL-positive and showed less disseminated disease and a tendency toward improved overall survival compared to HGAL-negative cases. This supports that a majority of RA-DLBCL are of non-GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA-DLBCL.
弥漫性大B细胞淋巴瘤(DLBCL)可根据CD10、BCL6和MUM1/IRF4的状态分为生发中心(GC)样和非GC样亚型。我们之前报道过,重度类风湿关节炎(RA)患者发生非GC DLBCL的风险增加。本研究检测了类风湿关节炎相关弥漫性大B细胞淋巴瘤(RA-DLBCL)中的一种新的GC标志物——人类生发中心相关淋巴瘤(HGAL)蛋白。在111例DLBCL中,38例(34%)HGAL呈阳性,与HGAL阴性病例相比,疾病播散较少,且总体生存率有改善趋势。这支持了大多数RA-DLBCL起源于非GC,表明活化的外周B细胞在RA-DLBCL发病机制中具有特定作用。